| Cash Flow | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Revenue From Contract With Customer Excluding Assessed Tax | NaN | 18,615 | 65,324 | NaN |
| License | NaN | NaN | 0 | NaN |
| Total revenue | NaN | 18,615 | 65,324 | NaN |
| Research And Development Expense | NaN | 4,921 | NaN | NaN |
| Research and development-Virology | NaN | 4,921 | 60,547 | NaN |
| Research and development-Immunology | NaN | 14,203 | 34,666 | NaN |
| Research and development-Other Programs | NaN | 1,735 | 11,527 | NaN |
| General and administrative | NaN | 9,009 | 43,933 | NaN |
| Loss from operations | NaN | -11,253 | -85,349 | NaN |
| Interest expense | NaN | 3,083 | 7,681 | NaN |
| Interest and investment income, net | NaN | 2,422 | 9,442 | NaN |
| Change in fair value of series 1 nonconvertible preferred stock | NaN | NaN | 39 | NaN |
| Total other (expense) income, net | NaN | -661 | 1,800 | NaN |
| Loss before income taxes | NaN | -11,914 | -83,549 | NaN |
| Income tax (expense) benefit | NaN | 24 | -1,660 | NaN |
| Net loss | -13,091 | -11,938 | -18,700 | -63,189 |
| Stock-based compensation expense | 3,748 | 3,810 | 4,034 | 14,531 |
| Depreciation and amortization expense | 1,209 | 1,230 | 1,284 | 3,302 |
| Non-cash interest associated with the sale of future royalties | 233 | 696 | -630 | NaN |
| Non-cash royalty revenue | -773 | 1,879 | -1,737 | 2,020 |
| Premium paid on marketable securities | 281 | 756 | 0 | NaN |
| Amortization of premiums on marketable securities | -302 | -20 | 958 | -1,461 |
| Loss on disposal of property and equipment | 0 | 0 | 0 | -6 |
| Change in fair value of series 1 nonconvertible preferred stock | NaN | NaN | 39 | NaN |
| Accounts receivable | -684 | 1,611 | -1,451 | 1,687 |
| Prepaid expenses and other current assets | 2,468 | -4,248 | -1,650 | -2,173 |
| Non-cash interest associated with the sale of future royalties | NaN | NaN | NaN | -1,399 |
| Income tax receivable | 19 | 0 | -24 | -31,975 |
| Operating lease, right-of-use assets | -567 | -546 | -701 | -3,607 |
| Other long-term assets | 51 | 1 | -2 | 0 |
| Accounts payable | 2,478 | -63 | -723 | -588 |
| Accrued expenses | -716 | -5,176 | 2,418 | -2,360 |
| Operating lease liabilities | -533 | -834 | -147 | 1,384 |
| Other long-term liabilities | 9 | 9 | 8 | 21 |
| Net cash used in operating activities | -7,156 | -11,699 | -6,489 | -12,783 |
| Purchase of marketable securities | 41,950 | 148,624 | 68,621 | 141,008 |
| Proceeds from maturities and sale of marketable securities | 53,907 | 101,469 | 72,375 | 190,497 |
| Purchase of property and equipment | 15 | 143 | 1,458 | 11,438 |
| Net cash (used in) provided by investing activities | 11,942 | -47,298 | 2,296 | 38,051 |
| Proceeds from the sale of future royalties | NaN | NaN | 0 | NaN |
| Proceeds from october 2025 public offering, net of issuance costs of 4,802 | 0 | 69,948 | NaN | NaN |
| Payments for debt issuance costs | NaN | NaN | 0 | NaN |
| Payments on royalty sale liability, net of imputed interest | 7,039 | 5,856 | 8,362 | 18,124 |
| Payments for settlement of share-based awards | 305 | 97 | 10 | 267 |
| Proceeds from the exercise of stock options | 49 | 141 | 51 | 94 |
| Net cash provided by (used in) financing activities | -7,295 | 64,136 | -8,321 | -18,297 |
| Net increase in cash, cash equivalents and restricted cash | -2,509 | 5,139 | -12,514 | 6,971 |
| Cash, cash equivalents and restricted cash at beginning of period | 40,797 | 35,658 | 41,201 | NaN |
| Cash, cash equivalents and restricted cash at end of period | 38,288 | 40,797 | 35,658 | NaN |
ENANTA PHARMACEUTICALS INC (ENTA)
ENANTA PHARMACEUTICALS INC (ENTA)